Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CIA-Linked Investor Helped Quantum Systems Expand in US 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Add as a preferred source on Google
BUENA, N.J., March 13, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 28th Annual Healthcare Conference. The Conference is taking place March 20-21, 2018 at the Westin Grand Central, New York, NY.
Jason Grenfell-Gardner, President and CEO and Damian Finio, Chief Financial Officer of Teligent, Inc. will present on Tuesday March 20th at 8:00 a.m. ET.
The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
